38.72
-0.79%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cathay Biotech
Its shares trade on Shanghai under the ticker 688065.SS. It has been listed since 12 August 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.30bn and net income of CN¥565.7m. At that date it held total assets of CN¥23.88bn and shareholders' equity of CN¥21.22bn.
Cathay Biotech Inc. engages in the research and development, production and sales of new bio-based materials. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-08-12. The firm's primary products are biological long-chain dibasic acids and bio-based polyamide series, including lauric acid and brazilian acid, which are used in long-chain polyamides, fragrances, hot melt adhesives, lubricants, powder coatings and other areas. The firm sells its products to domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 12 Aug 2020
- Employees
- 2,324
- Website
- cathaybiotech.com ↗
Leadership
Pay as last reported
- Dr. Xiucai LiuChairman of the Board, President, since 2019CN¥4.1m
- Mr. Chen YangChief Operating Officer, Vice PresidentCN¥1.0m
- Ms. Huiqing ZangVice President, Secretary of the Board, Director, since 2019CN¥1.1m
- Mr. Yijun DuVice PresidentCN¥1.3m
- Mr. Benliang HouVice PresidentCN¥783,200
- Mr. Hongguang ZhangVice PresidentCN¥1.1m
- Mr. Jun ZuoVice PresidentCN¥2.1m
- Mr. William KellerDirectorCN¥535,600
- Mr. Joachim RudolfDirector, since 2019CN¥789,800
- Mr. Faqin LuIndependent DirectorCN¥100,000
- Ms. Xiangyang WuIndependent DirectorCN¥100,000
- Mr. Bing ZhangIndependent DirectorCN¥100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 99
- Social
- 89
- Governance
- 56
- Women in the workforce
- 16.14%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cathay Biotech's primary products include biological long-chain dibasic acids and bio-based polyamide series.
- The company employs 2,324 full-time employees in Shanghai, China.
- Cathay Biotech sells products to both domestic and overseas markets.
Weaknesses
- The company's products are limited to biological long-chain dibasic acids and bio-based polyamide series.
- Cathay Biotech's business is concentrated in the Chemicals sector within Materials.
- The firm's primary products are used in specific applications like fragrances and lubricants.
Opportunities
- Expanding into new markets for bio-based polyamide series products.
- Increasing demand for sustainable materials in the Chemicals industry.
- Growing global interest in bio-based materials for industrial applications.
Threats
- Competition from traditional chemical manufacturers in the Materials sector.
- Regulatory changes affecting bio-based material production in China.
- Economic downturns impacting the Chemicals industry's growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.